Real-World Analysis of Outcomes in Older Women with HER2-Positive Advanced Breast Cancer

Conference Correspondent  - SABCS Highlights

For patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, the availability of anti-HER2 therapies has greatly improved disease outcomes. However, older patients are consistently underrepresented in clinical trial. For example, only approximately 2.4% of patients aged >75 years were included in the pivotal CLEOPATRA study.

Advanced age at time of diagnosis is associated with a higher likelihood of not receiving initial systemic therapy for de novo metastatic breast cancer. Studies have also shown that older women diagnosed with metastatic breast cancer have poorer prognostic outcomes and a shorter life expectancy. Nicole Evans of Eastern Health, Box Hill, Victoria, Australia, and colleagues examined “real world” treatment patterns and outcomes in an elderly (defined as ≥70 years of age) Australian population.

The researchers extracted data from the Treatment of Advanced Breast Cancer in the HER2-Positive Australian Patient (TABITHA) multisite clinical registry and stratified patients according to age (<70 and ≥70 years). They identified a total of 319 patients, including 67 (21%) patients aged ≥70 years.

In the study, older patients were more likely to have an Eastern Cooperative Oncology Group performance status ≥2 (16% vs 3%; P <.001). The researchers reported no significant differences in hormone receptor status, de novo metastatic presentation, or presence of visceral disease between groups. A similar percentage of patients in each group received first-line HER2-directed therapy (85% vs 93%; P = .054), and the duration of therapy was not significantly different between groups (16 months vs 22 months; P = .70). Although there was no difference between groups in the proportion of patients who were treated with first-line chemotherapy, older patients showed shorter duration of chemotherapy (2.7 months vs 3.5 months; P <.02). In younger patients, median overall survival was significantly longer at 82 months compared with 42 months (P <.001). Overall adverse event rates were higher in the older group (34% vs 20%; P = .04), including cardiotoxicity (7% vs 0.9%; P = .02) and on-treatment deaths (5% vs 0%; P = .01), in the first-line setting.

Despite having similar treatment patterns and disease characteristics, elderly patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events. To improve outcomes in the elderly HER2-positive population prospective studies are necessary.

Source: Evans N, Anton A, Wong R, et al. Real world outcomes in elderly women with HER2 positive advanced breast cancer. Presented at: 2020 San Antonio Breast Cancer Symposium, December 8-11, 2020. Abstract PS6-35.

Related Items
Health-Related Quality of Life in Patients with Metastatic Breast Cancer and Brain Metastases Treated with Tucatinib in Combination with Trastuzumab plus Capecitabine
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
NALA Phase 3 Trial Outcomes in Patients Treated with Neratinib or Lapatinib
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
HER2CLIMB-02: A Randomized, Double-Blind, Phase 3 Study of Tucatinib with T-DM1 for the Treatment of Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Final Overall Survival Analysis from the Randomized Phase 3 ExteNET Trial of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Hormone Receptor Status Is Not a Factor in the HER2CLIMB Study of Tucatinib Combination Treatment for Patients with HER2-Positive Metastatic Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Comparison of ARX788 and Lapatinib/Capecitabine in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Efficacy, Safety, and Tolerability of Tucatinib in Combination with Letrozole and Palbociclib in Patients with HR-Positive, HER2-Positive Metastatic Breast Cancer
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Use of Circulating Tumor Cells to Guide Treatment with HER2 Therapy
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Effect of Brain Metastases in Real-World Treatment Patterns and Healthcare Resource Utilization Among HER2-Positive Metastatic Breast Cancer Patients
Conference Correspondent  published on January 4, 2021 in SABCS Highlights
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Conference Correspondent  published on December 8, 2017 in SABCS Highlights
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: